AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
Failed to import article template. Reason: Failed to fetch dynamically imported module: ...
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
Zacks.com on MSN15h
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
AbbVie CEO Robert Michael told analysts during the company's second-quarter earnings call in July that “our ex-Humira growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback